Latest News
Real consumer spending (about 70% of the U.S. economy) on a monthly basis is negative for 2025.
Via Talk Markets · August 1, 2025
Via Benzinga · August 1, 2025
Stocks sold off into the weekend, as jobs data and renewed tariff tensions handicapped Wall Street to start August.
Via Talk Markets · August 1, 2025
Via Talk Markets · August 1, 2025
While one observation doesn’t make a trend (+73K consensus vs. +106K for NFP), three observations might.
Via Talk Markets · August 1, 2025
Centrus got hit along with other nuclear stocks today, but it's profitable, net debt-free, and still a solid company.
Via The Motley Fool · August 1, 2025
Via Benzinga · August 1, 2025
There might be a new way for certain users to defray their costs for obesity treatments.
Via The Motley Fool · August 1, 2025
Investors can tap two hot trends with one stock.
Via The Motley Fool · August 1, 2025
A weak jobs report was good news for Opendoor.
Via The Motley Fool · August 1, 2025
The Canadian Dollar caught a much-needed boost against the US Dollar on Friday.
Via Talk Markets · August 1, 2025
Figma shares traded higher on Friday, continuing to draw investor attention after a volatile debut session on Thursday that saw the stock surge over 250% following its initial public offering.
Via Benzinga · August 1, 2025
Nobody wants to own COIN shares short-term, it seems. After all, its results did not spark a lot of confidence.
Via Talk Markets · August 1, 2025
Palantir will report its second-quarter earnings after the closing bell on Aug. 4.
Via The Motley Fool · August 1, 2025
Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.
Via MarketBeat · August 1, 2025
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
The market may be realizing that Amazon might not generate strong FCF for a while, as its AI-related spending continues to surge.
Via Talk Markets · August 1, 2025
Carvana's stock (CVNA) has made a dramatic comeback, soaring 11,000%+ to an all-time high and providing opportunities for ETFs to ride the wave.
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
Via Benzinga · August 1, 2025
Flagship drugs Wegovy and Ozempic face slowing sales due to competition, generics, and U.S. regulatory heat.
Via Talk Markets · August 1, 2025
Via Benzinga · August 1, 2025
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via Chartmill · August 1, 2025
Can the EV maker follow its uphill path to profitability?
Via The Motley Fool · August 1, 2025
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Via Benzinga · August 1, 2025